Literature DB >> 35460687

Impact Of The COVID-19 Pandemic on Hospital Admissions and In-Hospital Lethality From Cardiovascular Diseases in Brazil: An Ecological and Time Series Study.

Lucas Gomes Santos1, Regicley Vieira da Silva2, Thiago Cavalcanti Leal3, José Emerson Xavier4, Elaine Virgínia Martins de Souza Figueiredo5, João Paulo Silva de Paiva2, Leonardo Feitosa da Silva2, Carlos Alberto de Oliveira Rocha2, Bruno Eduardo Bastos Rolim Nunes2, Gibson Barros de Almeida Santana2, Tânia Rita Moreno de Oliveira Fernandes5, Francisco de Assis Costa2, Márcio Bezerra-Santos4, Rodrigo Feliciano do Carmo6, Anderson da Costa Armstrong5, Carlos Dornels Freire de Souza2.   

Abstract

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic in Brazil, several government policies have been taken. Herein, we aimed to assess the impact of the COVID-19 pandemic on hospital admissions and in-hospital lethality for cardiovascular diseases (CVD) in Brazil in 2020. An ecological and time-series study on hospitalizations and deaths from CVD in Brazil was conducted from January 2018 to December 2020.The hospital admission rate for CVD reduced by 17.1%, with a significant decreasing trend between January and May 2020 (Annual Percent Change: -8,7%; P-value < 0.001). The in-hospital lethality rate increased from 8.2% in 2018 to 9.3% in 2020. During this period, Brazil totaled 21.8 million days of hospital stay. Indicators of hospital admissions and lethality from CVD in Brazil were impacted by the emergence of the COVID-19 pandemic in different ways in the regions and depending on the nature of the indicator.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Year:  2022        PMID: 35460687      PMCID: PMC9021219          DOI: 10.1016/j.cpcardiol.2022.101216

Source DB:  PubMed          Journal:  Curr Probl Cardiol        ISSN: 0146-2806            Impact factor:   16.464


Introduction

The new coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2 - SARS-CoV-2) is part of a set of viruses in the Coronaviridae family. Viruses from this family have been previously observed in other smaller outbreaks, such as SARS-CoV-1 and MERS-CoV (Mediterranean Acute Respiratory Syndrome Coronavirus) reported in 2002 and 2012, in China and the Middle East, respectively. In December 2019, an outbreak of rapidly progressing pneumonia was identified in Wuhan, capital of Hubei province, China. On January 7, 2020, China attributed the outbreak to SARS-CoV-2 and the disease was named Coronavirus Disease 2019 (COVID-19). The outbreak caused by the new coronavirus was declared a pandemic by the World Health Organization (WHO) on March 11, 2020 and, since then, the disease has brought extraordinary challenges to health authorities and governments in several countries worldwide. In Brazil, the first case of COVID-19 was confirmed on February 26 and the first death on March 17. The national community transmission was recognized on March 20, 2020 by the Brazilian Ministry of Health. The first case was confirmed in the city of São Paulo in a patient from Italy, but the disease rapidly spread to the large metropolises of other regions until it reached smaller and more distant cities.5, 6, 7 Despite all WHO recommendations, and the enactment of Law No. 13.979/2020 on February 7, 2020 (which provides for measures to combat COVID-19 in the country), restrictive measures for the movement of people, such as banning events with agglomeration in several states and closing all non-essential commerce were only implemented in late March. As a result, in July 2020 the first wave of the pandemic was observed in the country, with a daily average of 70 thousand new cases of COVID-19. To date, Brazil ranks second in the world in number of deaths by COVID-19. Remarkable, the COVID-19 pandemic has been causing significant impacts on public health and the global economy. Furthermore, the measures to restrict the mobility of people and the redirection of health services to fight the transmission of the virus have also affected the control of several other diseases such as cancer, dementia, and high blood pressure.10, 11, 12 Additionally, this impact occurs directly, in patients with any comorbidity, especially chronic diseases; and indirectly, by changing the behavior of the population, such as fear of contagion and reduced demand for health services. , Importantly, the implementation of collective measures of social distancing to contain COVID-19 resulted in changes in the routine of services. As a result, this promoted the rescheduling of elective procedures and the redistribution of hospital flow to transform face-to-face hospital care into distance care (tele-health) in several clinical situations. To illustrate this impact, in an oncology center in São Paulo, there was a reduction of 45% in the number of patients treated and 57.4% in the number of patients undergoing systemic intravenous treatment. Clinically, there is an important relationship between COVID-19 and cardiovascular diseases (CVD), such as: i. the impact of CVD on the worsening of COVID-19, which is an relevant set of predictors of severity and mortality; ii. the damage caused by SARS-CoV-2 in the cardiovascular system (CS) of people without underlying disease due to pathophysiological mechanisms of virus infection; and iii. the worsening of CVD in individuals without COVID-19, but as a result of non-pharmacological preventive measures to reduce the circulation of the virus, such as hospital evasion of patients, delaying the care of episodes of exacerbation of these chronic conditions or making early diagnosis difficult. , Herein, we aimed to assess the impact of the COVID-19 pandemic on hospital admissions and in-hospital lethality for CVD in Brazil during the first year of the pandemic.

Methods

Study Design, Area, Population, And Period

An ecological and time-series study was conducted on hospitalizations and deaths from CVD in Brazil and its regions from January 2018 to December 2020. Data on CVD for the years 2018 and 2019 were used as the period before the COVID-19 pandemic and were compared with data for 2020.

Study Variables and Data Collection

Herein, the following variables were assessed: i. hospital admissions rate for CVD (Chapter IX of the ICD-10) per month (from January 2018 to December 2020); ii. in-hospital lethality rate due to CVD per month (from January 2018 to December 2020); iii. total cost applied (in Brazilian reais - R$) and average cost (R$) of hospitalizations for CVD; iv. days of hospital stay and average time of stay (in days) for CVD; v. new COVID-19 cases registered per month. To calculate the rates, the following equations were applied: hospital admissions rate for CVD in-hospital lethality rate due to CVD Data on hospitalizations and deaths due to CVD were extracted from the Hospital Information System (SIH) of the Brazilian Unified Health System (SUS) (http://www2.datasus.gov.br/DATASUS/index.php?area=0203&id=6926). The SIH is a nationwide information system, created in 1991, for the registration of medical and hospital assistance within the SUS based on Hospital Admission Authorizations (AIH) and managed by the Brazilian Ministry of Health (BRASIL, 2004). The main purpose of this system is to generate information on hospitalizations and deaths that can be used in decision-making and public management in Brazil (BRASIL, 2004; ROCHA et al., 2018). Importantly, these data were collected according to the year and month of hospitalization. COVID-19 data were extracted from the consolidated data of the Brazilian Ministry of Health and the State Health Departments by the covid19br platform (ttps://covid19br.wcota.me/). Finally, population data were obtained from the Brazilian Institute of Geography and Statistics (IBGE).

Statistical Treatment of Data

The statistical analysis of the data took place in 3 steps: Descriptive analysis of epidemiological indicators: at this stage, the indicators were described in a monthly time series between January 2018 and December 2020. We also included the year 2018 in order to verify the possible existence of variations in the indicators in 2019. Random variations in 2019, for example, could compromise the assessment of the impact of the pandemic on the assessed epidemiological indicators. Percentage variation analysis since no random variations were observed in the indicators for the years 2018 and 2019, the percentage variation in the period was calculated, considering each month of the year 2020 in relation to the same month of 2019. Positive proportional variations indicate an increase in the indicator and negative proportional variations indicate a reduction in the value. Time series analysis Finally, the 2020 data were subjected to temporal trend analysis by the inflection point regression model (joinpoint regression model). This model tests whether a line with multiple segments is statistically better at describing the time evolution of a dataset than a straight line or a line with fewer segments. In this sense, the model allows identifying the trend of the indicator (if stationary, increasing, or decreasing) and the points where there is a change in this trend (joins). For that, we calculated the annual percentage changes (APC), for segmented periods, and the average annual percentage changes (AAPC), for the entire period. Time trends were considered statistically significant when APC or AAPC had a P-value < 0.05 and their CI 95% did not include the zero. Importantly, a positive and significant APC or AAPC indicates an increasing trend; on the other hand, a negative and significant APC or AAPC indicates a decreasing trend; and non-significant trends are described stable, regardless of APC or AAPC values. The analyses were performed in the software Joinpoint Regression Program version 4.5.0.1 (National Cancer Institute- USA).

Ethical Aspects

This study used data from the public domain, which does not allow the identification of the subjects. For this reason, the appreciation of the Research Ethics Committee was waived.

Results

Hospital Admissions Rate For CVD

A total of 3.3 million hospitalizations for CVD were recorded in Brazil between 2018 and 2020. The average annual rate was 55.2 in 2018, 56.1 in 2019, and 46.5/10,000 inhabitants in 2020 (reduction of 17.1% compared to 2019). In March 2020, there was a decline of 4.1% in the hospitalization rate, as observed in all subsequent months, especially in July and August (both with a drop of 25.3%) ( Fig 1 A).
FIG 1

Temporal evolution of hospital admission rates (10 thousand inhabitants) and in-hospital mortality (100 admissions) for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.)

Temporal evolution of hospital admission rates (10 thousand inhabitants) and in-hospital mortality (100 admissions) for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.) During the study period, the South region showed the highest hospitalization rates (86.1 in 2018, 87.1 in 2019 and 71/10,000 in 2020). Meanwhile, the lowest rates were observed in the North region (9.8 in 2018, 28.7 in 2019 and 22.8/10,000 in 2020). In addition, the North showed the greatest reduction in the rate between 2019 and 2020 (-20.2%) and the greatest instability among the regions of the country (Fig 1G). The highest reductions in hospital admissions occurred at different times between regions in 2020: North (-48.9% in December), Northeast (-30.9% in August), Midwest (-27.9% in August), South (-26.6% in July), and Southeast (-26.4% in May) (Fig 1B-F). A decreasing temporal trend was observed in the hospital admissions rate for CVD in Brazil between January and May 2020 (APC: -8.7; P-value < 0.001). This same trend was observed in the Northeast (APC: -10.2; P-value < 0.001), Southeast (APC: -8.3; P-value < 0.001), and South regions (APC: -8.9; P-value < 0.001). The North (AAPC: -4.2; P-value < 0.001) and Central-West regions (AAPC: -2.4; P-value < 0.001) showed a decreasing trend throughout all the months of 2020 (Table 1 ).
Table 1

Temporal analysis (joinpoint regression model) of the hospitalization rate (10 thousand inhabitants), for cardiovascular diseases in Brazil and regions between January and December 2020

RegionPeriodAPC/AAPC (P-value)TrendJoinpoint regression model
NorthJan/20 - Dec/20-4.2 (<0.001) *Image, table tbI
NortheastJan/20 – May/20-10.2 (<0.001) *Image, table tbI
May/20 – Oct/204.8 (0.1)
Oct/20 – Dec/20-5.6 (0.5)
Jan/20 – Dec/20-2.8 (0.1)
SoutheastJan/20 – Mai/20-8.3 (<0.001) *Image, table tbI
May/20 – Oct/204.7(<0.001) *
Oct/20 – Dec/20-5.4 (0.5)
Jan/20 – Dec/20-2.0 (0.2)
SouthJan/20 – Mai/20-8.9 (<0.001) *Image, table tbI
May/20 – Oct/203.6 (0.3)
Oct/20 – Dec/20-7.0 (0.6)
Jan/20 – Dec/20-3.0 (0.3)
Central-WestJan/20 – Jul/20-3.5 (<0.001) *Image, table tbI
Jul/20 – Dec/20-1.0 (0.2)
Jan/20 – Dec/20-2.4 (<0.001) *
BrazilJan/20 – May/20-8.7 (<0.001) *Image, table tbI
May/20 – Oct/203.8 (0.1)
Oct/20 – Dec/20-5.6 (0.6)
Jan/20 – Dec/20-2.6 (0.2)

Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

Temporal analysis (joinpoint regression model) of the hospitalization rate (10 thousand inhabitants), for cardiovascular diseases in Brazil and regions between January and December 2020 Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

In-Hospital Lethality Rate Due To CVD

The in-hospital lethality rate for CVD in Brazil was 8.2% in 2018, 8.3% in 2019, and 9.3% in 2020 (12.5% increase compared to 2019). Differently from what was observed in the hospitalization rate, the in-hospital lethality rate in Brazil showed an increase of 21.3% in April 2020, with a peak in May (25%) and with percentages above 12% in all other months of the year (Fig 2 A).
FIG 2

Temporal evolution of in-hospital lethality rate (100 admission), for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.)

Temporal evolution of in-hospital lethality rate (100 admission), for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.) Among this period, the North region had the highest lethality rates in 2018 and 2019 (9.2% and 9.8%, respectively). In 2020, the highest rate was identified in the Central-west region (10.7%). On the other hand, the South region showed the lowest rates (6.4% in 2018, 6.5% in 2019, and 7.63% in 2020) ( Fig 2B-F). Additionally, the North region showed the biggest increase in the lethality rate (+31.45%) between the months of February and June 2020, followed by the Northeast region, with a peak of lethality in May (+11.76%) (Fig 2G). Importantly, we observed an increasing trend in the lethality rate in Brazil between January and June 2020 (APC: 6.0; P-value < 0.001), with a subsequent reduction between June and December (APC: -2.9; P-value < 0.001). Likewise, similar trends (P-value < 0.001) were observed in these months (January/June and July/December) in the Northeast (APC: 7.9 and APC: -2.8), Southeast (APC: 6.3 and APC: -3.0) and Central-West regions (APC: 2.9 and APC: -6.9. Interestingly, the North (APC: 6.3; P-value < 0.001) and South regions (APC: 5.9; P-value < 0.001) showed an increasing trend during the first half of 2020 ( Table 2 ).
Table 2

Time series analysis (joinpoint regression model) of the in-hospital lethality rate (%) due to diseases of circulatory system in Brazil and regions between January and December 2020

RegionPeriodAPC/AAPC (P-value)TrendJoinpoint regression model
NorthJan/20 – June/206.3(<0.001) *Image, table tbII
June/20 – Sept/20-8.0 (0.2)
Sept/20 – Dec/203.3 (0.2)
Jan/20 – Dec/201.4 (0.3)
NortheastJan/20 – May/207.9 (<0.001) *Image, table tbII
May/20 – Dec/20-2.8 (<0.001) *
Jan/20 – Dez/200.9 (0.3)
SoutheastJan/20 – June/206.3 (<0.001) *Image, table tbII
June/20 – Dec/20-3.0 (<0.001) *
Jan/20 – Dec/201.1 (0.2)
SouthJan/20 – Jul/205.9 (<0.001) *Image, table tbII
Jul/20 – Dec/20-3.2 (0.1)
Jan/20 – Dec/201.7 (0.1)
Central-WestJan/20 – Sept/202.9 (<0.001) *Image, table tbII
Spet/20 – Dec/20-6.9 (<0.001) *
Jan/20 –Dez/200.2 (0.8)
BrazilJan/20 – June/206.0 (<0.001) *Image, table tbII
June/20 – Dec/20-2.9 (<0.001) *
Jan/20 – Dec/201.1 (0.3)

Legend: APC: annual percentage change; AAPC: average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

Time series analysis (joinpoint regression model) of the in-hospital lethality rate (%) due to diseases of circulatory system in Brazil and regions between January and December 2020 Legend: APC: annual percentage change; AAPC: average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

Total Cost (in Brazilian Real - R$) And Average Cost (R$) of Hospitalizations for CVD

During the study period, R$8.8 billion were spent on hospitalizations for CVD throughout Brazil, with an average cost of R$2.6 thousand per each hospitalization. The highest cost was observed in 2019 (R$3.1 billion) and the lowest in 2020 (total cost of R$2.8 billion − a reduction of 10.3%). In addition, there was reduction in total cost from April (-15.8%) to December 2020 (Fig 3 A). Conversely, the average cost of each hospitalization ranges from R$2.6 to R$2.8 thousand reais (an increase of 7.4%). Moreover, there was increase in every month of 2020, mainly in March (+5.4%), August (+11.5%), and December (+13.3%) (Fig 4 A).
FIG 3

Temporal evolution of total cost of hospital admission for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.)

FIG. 4

Evolution temporal of the average cost of hospital admission for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.)

Temporal evolution of total cost of hospital admission for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.) Evolution temporal of the average cost of hospital admission for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.) As expected, the highest hospitalization costs were identified in the Southeast region (annual average of R$1.3 billion) and the lowest in the North (annual average of R$93.9 million). The South region showed the greatest reduction in costs (-14%) ( Fig 3B-F). Interestingly, all regions showed an increase in the average cost of admissions, being higher in the South (annual average of R$3.1 thousand per admission) and lower in the North (annual average of R$1.9 thousand). Furthermore, the North region was the one with the greatest instability in the average cost throughout 2020, with the lowest percentage in January (-4%) and the highest in December (24.8%) (Fig 4G). Time trend analysis showed a stationary trend of the total cost of hospitalizations for CVD in Brazil throughout 2020 (APC: -1.0%). On the other hand, the national average cost per hospitalization showed an increasing trend (AAPC: 1.2%; P-value < 0.001). Among the regions, the North was the only one with a decreasing trend in 2020 (APC: -3.3; P-value < 0.001). In the Northeast and Southeast regions, there was a reduction between January and May 2020 (APC: -8.0 and -5.9, respectively; P-value < 0.001), followed by an increasing from May to December (APC: 4.3 and 2.7, respectively; P-value < 0.001) (Table 3 and 4 ).
Table 3

Temporal analysis (joinpoint regression model) of the total cost per hospital stay for cardiovascular diseases in Brazil and regions between January and December 2020.

RegionPeriodAPC/AAPC (P value)TrendJoinpoint regression model
NorthJan/20 – Dec/20-3.3 (<0.001) *Image, table tbIII
NortheastJan/20 – May/20-8.0 (<0.001) *Image, table tbIII
May/20 – Dec/204.3 (<0.001) *
Jan/20 – Dec/20-0.3 (0.8)
SoutheastJan/20 – May/20-5.9 (<0.001) *Image, table tbIII
May/20 – Dec/202.7 (<0.001) *
Jan/20 – Dec/20-0.6 (0.5)
SouthJan/20 – Dec/20-1.6 (0.1)Image, table tbIII
Central-WestJan/20 – Oct/20-2.2 (<0.001) *Image, table tbIII
Oct/20 – Dec/205.1 (0.3)
Jan/20 – Dec/20-0.9 (0.3)
BrazilJan/18 – May/20-6.3 (<0.001) *Image, table tbIII
May/20 – Dec/202.1 (0.1)
Jan/20 – Dec/20-1.0 (0.3)

Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

Table 4

Temporal analysis (joinpoint regression model) of the average cost per hospital stay for diseases of the circulation system in Brazil and regions between January and December 2020

RegionPeriodAPC/AAPC (P value)TrendJoinpoint regression model
NorthJan/20 - Dec/201.2 (0.1)Image, table tbIV
NortheastJan/20 – Dec/201.6 (<0.001) *Image, table tbIV
SoutheastJan/20 – Dec/200.6 (0.1)Image, table tbIV
SouthJan/20 – Dec/20-0.0 (1.0)Image, table tbIV
Central-WestJan/20 – Mar/20-1.9 (0.6)Image, table tbIV
Mar/20 – June/203.8 (0.4)
June/20 – Oct/20-2.0 (0.3)
Out/20 – Dec/208.6 (0.2)
Jan/20 – Dec/201.4 (0.1)
BrazilJan/18 – Apr/202.4 (<0.001) *Image, table tbIV
Apr/20 – Oct/20-0.3 (0.4)
Oct/20 – Dcz/203.9 (<0.001) *
Jan/20 – Dec/201.2 (<0.001) *

Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

Temporal analysis (joinpoint regression model) of the total cost per hospital stay for cardiovascular diseases in Brazil and regions between January and December 2020. Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance. Temporal analysis (joinpoint regression model) of the average cost per hospital stay for diseases of the circulation system in Brazil and regions between January and December 2020 Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

Length Of Stay and Average Hospital Stay (In Days) For CVD

There was a total of 21.8 million days of hospitalization for CVD in Brazil (annual average of 7.3 million) between 2018 and 2020. During this period, the average length of stay was 6.5 days. In 2020, there was a reduction of 17.1% in the total period of hospitalizations and a reduction of 1.5% in the average length of stay. With the onset of the pandemic, there was a significant reduction in the total period of hospitalizations, mainly in July (-27.2%) and August 2020 (-27.6%) (Fig 5 and 6 ).
FIG 5

Temporal evolution of total of days of hospital stay for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.)

FIG 6

Temporal evolution of the average days of hospital stay for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.)

Temporal evolution of total of days of hospital stay for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.) Temporal evolution of the average days of hospital stay for CVD in Brazil and regions, before and after confirmation of the COVID-19 pandemic (Color version of figure is available online.) In the study period, the Southeast region showed the highest number of days of hospitalization for CVD (annual average of 3.4 million days) and the North had the lowest (344.9 thousand days). As of April 2020, all regions showed a reduction in the sum of days. In addition, the North was the region with the greatest reduction in 2020 (-20.7%) (Fig 5). The average length of stay was longer in the Northeast region (7.2 days) and shorter in the South (5.4 days) (Fig 6). Importantly, the sum of days of hospitalization showed a decline trend in Brazil (AAPC: -2.1; P-value < 0.001). Similarly, there was a decreasing trend in the North (AAPC: -5.5; P-value < 0.001) and Central-West regions (AAPC: -2.4; P-value < 0.001) (Table 5 ). Regarding the average number of days of stay, there was a stationary trend in the country (AAPC: 0.0). Also, there was an increasing trend in the Northeast (AAPC: 0.2; P-value < 0.001) and a reduction in the North region (AAPC: -1.0; P-value < 0.001) (Table 6 ).
Table 5

Temporal analysis (joinpoint regression model) of the total days of hospital stay for cardiovascular diseases in Brazil and regions between January and December 2020

RegionPeriodAPC/AAPC (P-value)TrendJoinpoint regression model
NorthJan/20 – Dec/20-5.5 (<0.001) *Image, table tbV
NortheastJan/20 – June/20-8.5(<0.001) *Image, table tbV
Jun/30 – Dec/204.1(<0.001) *
Jan/20 – Dec/20-1.9 (0.1)
SoutheastJan/20 – May/20-7.3 (<0.001) *Image, table tbV
May/20 – Dec/201.8 (0.1)
Jan/20 – Dec/20-1.6 (0.1)
SouthJan/20 – Dec/20-1.2 (0.1)Image, table tbV
Central-WestJan/20 – Aug/20-5.4 (<0.001) *Image, table tbV
Aug/20 – Dec/203.0 (0.1)
Jan/20 – Dec/20-2.4 (<0.001) *
BrazilJan/18 – May/20-8.1 (<0.001) *Image, table tbV
May/20 – Dec/201.5 (0.2)
Jan/20 – Dec/20-2.1 (<0.001) *

Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

Table 6

Temporal analysis (joinpoint regression model) of the average days of hospital stay for cardiovascular diseases in Brazil and regions between January and December 2020

RegionPeriodAPC/AAPC (P value)TrendJoinpoint regression model
NorthJan/20 – Dec/20-1.0 (<0.001) *Image, table tbVI
NortheastJan/20 – Apr/200.2 (<0.001) *Image, table tbVI
Apr/20 – Jul/20-3.2 (<0.001) *
Jul/20 – Oct/201.1(<0.001) *
Oct/20 – Dec/204.0 (<0.001) *
Jan/20 – Dec/200.2 (<0.001) *
SoutheastJan/20 – Mar/202.5 (0.4)Image, table tbVI
Mar/20 – Oct/20-1.5 (<0.001) *
Oct/20 – Dec/203.9 (0.3)
Jan/20 – Dec/200.2 (0.8)
SouthJan/20 – Dec/200.3 (0.1)Image, table tbVI
Central-WestJan/20 – Sept/20-2.2 (<0.001) *Image, table tbVI
Sept/20 – Dec/206.5 (<0.001) *
Jan/20 – Dec/200.1 (0.9)
BrazilJan/18 – Oct/20-0.8 (<0.001) *Image, table tbVI
Oct/20 – Dec/203.7 (0.3)
Jan/20 – Dec/200.0 (1.0)

Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

Temporal analysis (joinpoint regression model) of the total days of hospital stay for cardiovascular diseases in Brazil and regions between January and December 2020 Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance. Temporal analysis (joinpoint regression model) of the average days of hospital stay for cardiovascular diseases in Brazil and regions between January and December 2020 Legend: APC, annual percentage change; AAPC, average annual percentage change ↔Stable; ↓Decreasing; ↑Increasing. *Statistical significance.

Discussion

Altogether, our analyses showed a reduction in hospital admissions for CVD, in the total cost of these admissions, in the absolute number and average length of hospital stay after the emergence of COVID-19 pandemic in Brazil. On the other hand, there was an increase in the in-hospital lethality rate and in the average cost of admissions. Importantly, these variations occurred unequally in time (over months) and in space (between regions), reflecting different aspects of the impact of the pandemic throughout Brazilian regions. The reduction in hospitalizations for CDV may be the result of 2 important aspects that became present with the onset of the COVID-19 in Brazil: changes in the behavior of individuals, which caused less search for and/or evasion of health services; and aspects directly related to changes in the structure and functioning of health services, such as the reduction of outpatient care and the relocation of health professionals to fight the pandemic (BORGES, 2020). Notably, these changes are consequences of the implementation of a wide range of non-pharmacological measures aimed at containing the spread of the SARS-CoV-2 in the Brazilian territory. Initially, the pandemic caused important changes in the behavior of the population, which may have resulted in reduced access to health services. Likewise, the need for social distancing to control the spread of the virus seems to have acted as a factor generating fear of contamination in health facilities. Additionally, there was reduction of urban mobility and access to health services by the population. Taken together, these factors may have influenced the evasion of patients from different health services, whether in primary care, responsible for managing risk factors-chronic diseases, or in specialized-hospital centers. , , Similarly, the reduction in hospitalizations for CVD was also observed in other studies worldwide. , Corroborating our findings, a study conducted in New York (USA) observed a significant reduction in acute hospitalizations for chronic diseases in 2020, including cardiovascular diseases. Importantly, the delay in patient care, observed in many countries, has resulted in serious clinical conditions rarely seen outside this context, such as cardiogenic shock and ventricular rupture due to acute myocardial infarction (AMI), which significantly increases risk of death from CVD. In Brazil, an investigation carried out with more than 45 thousand individuals showed that people with CVD had greater adherence to measures of social distancing. Remarkable, this scenario can be justified by different factors, such as: i. association between the presence of CVD and increased risk of death from COVID-19; ii. the fear of SARS-CoV-2 infection; iii. the amount of information disseminated by the media and social networks (infodemic) , ; and iv. the dissemination of false and unscientific information (fake news). Taken together, they potentiated the negative effects of social isolation, causing fear, sadness, depression, anxiety, and sleep disturbances. Additionally, the same study conducted here showed that patients with chronic non-communicable diseases (NCDs) had more difficulty accessing health services during the pandemic. These services included health care, appointment bookings, and medication. It should be noted that chronic diseases, due to their typically long-lasting nature, demand more control actions and the provision of health services. As a result, the difficulties in accessing health services and the social isolation measures may have impacted on the reduction of hospital admissions and the increase in mortality from CVD. Regarding changes in the structure and functioning of health care services that may have reduced the number of admissions, we highlighted: i. the reallocation of resources (financial, human and material) to assist in cases of COVID-19, which may result in the depletion of these resources for other sectors; ii. the rescheduling of appointments with greater delay; iii. the preference for assistance via telemedicine , ; iv. reducing the daily working hours of services, health professionals and the number of daily appointments. On the other hand, following the increase in COVID-19 cases in the country, there was an increase in in-hospital mortality due to CVD, as also observed in previous studies in Brazil and in other countries. , In these studies, patients hospitalized with acute myocardial infarction, coronary artery disease, , or acute cardiac injury were more likely to have fatal outcomes when co-infected with SARS-CoV-2. Furthermore, this aggravating factor and the increased demand for health professionals may also explain the increase in the average cost per hospitalization observed in our study. More recently, COVID-19 started to be described in the scientific literature as a vascular disease, rather than respiratory disease, which increases the risk of pathophysiological interaction with CVD. This interaction and the consequences of the various vascular dysfunctions caused by COVID-19 increase the risk of lethality in individuals with CVD. Different factors, such as the activation of the immune system and the cytokine storm, prothrombotic state, and dysregulation of the Renin-Angiotensin-Aldosterone system led to events such as AMI and cerebrovascular accident (CVA). Notably, regional disparities in Brazil may be associated with variations in the impact of the pandemic. The North region had the highest mortality rate, and it may be related to the precariousness of the health system in the region. The asymmetric and reduced distribution of health resources in the territory and the concentration of medical treatments in the urban centers of Manaus (Capital of the State of Amazonas) and Belém (Capital of the State of Pará) results in a migratory process in search of care. As a result, there is acceleration of COVID-19′s internalization process and rapid collapse of the health network. , In addition, the increased severity of these patients at the time of admission significantly increases the chance of death. Hereupon, there is a reduction in the time of stay and, consequently, in the average cost of hospitalizations. This phenomenon can be exemplified by the high mortality rate due to COVID-19 observed in the state of Amazonas, which underwent a major collapse of the health system in May and December 2019, as consequence of the sharp rise in cases of COVID-19 and the inability of the health network to meet the demand. , Otherwise, a more homogeneous distribution of health resources among municipalities in the South region, with a greater offer of ICU beds, respirators, and health professionals in the territory can directly contribute to a better compatibility between hospital supply and demand. Notably, these regional disparities reflect the unequal development and concentration of wealth in the South and Southeast regions of the country and may have influenced the lower in-hospital lethality observed in this region. In fact, population with better living conditions has more access to health care services, which implies greater survival when compared to other populations without the same access facilities. The Central-West region, which was impacted later with the arrival of COVID-19, had an average of 2.5 hospital beds/10,000 inhabitants (about 8.5% of the total number of beds in the country). Despite being the second largest Brazilian region in terms of land area, it is the second least populated, and has the second smallest GDP among the other regions. In this region, about 80% of the population depends on the SUS and, during the pandemic, the Central-West had the second lowest number of ICU beds in the SUS, which contributed to a smaller variation in the rate of admissions and an increase in the in-hospital lethality rate for CVD. Furthermore, a study that assessed the population's adherence to measures to restrict physical contact and spread COVID-19 across the Brazilian regions showed that the residents of the Central-West were those with the lowest adherence to virus control measures. In addition, the Central-West had the lowest percentage of total restriction of physical contact (12.3%) and the highest percentage of people who did not undergo any type of restriction (3.3%), which may have contributed to the highest CVD in-hospital lethality rate. Alternatively, the groups with the highest membership were composed of residents of the Southeast and Northeast regions. Despite all efforts conducted by state governments to reduce hospitalization and deaths due to COVID-19 in Brazil, a second wave of the pandemic, even more severe, occurred first in the state of Amazonas (November 2020) and spread to other regions of the country in March 2021. This second wave may have occurred due to multiple factors, such as: behavioral (population neglect and relaxation of post-first wave social distancing measures); delays in acquiring vaccines and low mass immunity; and iii. emergence of new variant strains of the virus (such as B.1.1.28, P.1, B.1.195, B.1.1.33 and P.2) with greater potential for transmission. Unfortunately, this second wave caused chaos and collapse in health systems in all regions, which limited care for clinical complications and exacerbations in patients with CVD/COVID-19. Consequently, this may have increased the in-hospital lethality rate from CVD. Even considering all the methodological precautions, this study has some limitations. The increase in the in-hospital lethality rate may be overestimated due to the reduction in the number of admissions (the denominator of the equation). In addition, the use of secondary data that are subject to the influence of the operative capacity of health services, which are related to the possibility of confusion as to the cause of death, both for CVD and for COVID-19.

Conclusion

Our analyzes demonstrated the impact of the COVID-19 pandemic on indicators of hospital admissions and lethality from CVD in Brazil, with variations depending on the nature of the indicator and the region of the country. Herein, we observed an increase in the hospital admission rate, in-hospital lethality, in the total cost of admissions, and in the total number of hospitalization days for CVD. Conversely, there was a reduction in the average cost per hospitalization, and in the average number of days of hospitalization due to CVD. Therefore, the study data suggest that the pandemic affected both health services and the dynamics of patients' demand for care. As a result, there has been a reduction in access to health services, diagnosis, and timely treatment of other diseases, including CVD.
  25 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Factors associated with people's behavior in social isolation during the COVID-19 pandemic.

Authors:  Anselmo César Vasconcelos Bezerra; Carlos Eduardo Menezes da Silva; Fernando Ramalho Gameleira Soares; José Alexandre Menezes da Silva
Journal:  Cien Saude Colet       Date:  2020-04-23

3.  The impact of COVID-19 pandemic in the management of a Vascular Surgery Department.

Authors:  António Pereira-Neves; João Rocha-Neves; Marina Dias-Neto; Alfredo Cerqueira; José Fernando-Teixeira
Journal:  Rev Port Cir Cardiotorac Vasc       Date:  2020 Apr-Jun

4.  What is the role of Primary Health Care in the COVID-19 pandemic?

Authors:  Thiago Dias Sarti; Welington Serra Lazarini; Leonardo Ferreira Fontenelle; Ana Paula Santana Coelho Almeida
Journal:  Epidemiol Serv Saude       Date:  2020-04-27

5.  The need to strengthen Primary Health Care in Brazil in the context of the COVID-19 pandemic.

Authors:  Carlos Dornels Freire de Souza; Vanessa Tavares de Gois-Santos; Divanise Suruagy Correia; Paulo Ricardo Martins-Filho; Victor Santana Santos
Journal:  Braz Oral Res       Date:  2020-05-11

6.  COVID-19 and Myocardial Injury in a Brazilian ICU: High Incidence and Higher Risk of In-Hospital Mortality.

Authors:  Jorge Henrique Paiter Nascimento; Rafael Lessa da Costa; Luiz Fernando Nogueira Simvoulidis; João Carlos de Pinho; Roberta Santos Pereira; Andrea Dornelles Porto; Eduardo Costa de Freiras Silva; Liszt Palmeira Oliveira; Max Rogerio Freitas Ramos; Gláucia Maria Moraes de Oliveira
Journal:  Arq Bras Cardiol       Date:  2021-02       Impact factor: 2.000

Review 7.  Social distancing measures to control the COVID-19 pandemic: potential impacts and challenges in Brazil.

Authors:  Estela M L Aquino; Ismael Henrique Silveira; Julia Moreira Pescarini; Rosana Aquino; Jaime Almeida de Souza-Filho; Aline dos Santos Rocha; Andrea Ferreira; Audêncio Victor; Camila Teixeira; Daiane Borges Machado; Enny Paixão; Flávia Jôse Oliveira Alves; Flávia Pilecco; Greice Menezes; Ligia Gabrielli; Luciana Leite; Maria da Conceição Chagas de Almeida; Naiá Ortelan; Qeren Hapuk R. Ferreira Fernandes; Renzo Joel Flores Ortiz; Raquel Nunes Palmeira; Elzo Pereira Pinto Junior; Erika Aragão; Luis Eugenio Portela Fernandes de Souza; Manoel Barral Netto; Maria Glória Teixeira; Mauricio Lima Barreto; Maria Yury Ichihara; Raíza Tourinho dos Reis Silva Lima
Journal:  Cien Saude Colet       Date:  2020-04-22

8.  Subclinical coronary artery disease in COVID-19 patients.

Authors:  Luca Nai Fovino; Filippo Cademartiri; Giuseppe Tarantini
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-09-01       Impact factor: 6.875

9.  Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis.

Authors:  Xintao Li; Bo Guan; Tong Su; Wei Liu; Mengyao Chen; Khalid Bin Waleed; Xumin Guan; Tse Gary; Zhenyan Zhu
Journal:  Heart       Date:  2020-05-27       Impact factor: 5.994

10.  Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak.

Authors:  Jorge Solano-López; José Luis Zamorano; Ana Pardo Sanz; Ignacio Amat-Santos; Fernando Sarnago; Enrique Gutiérrez Ibañes; Juan Sanchis; Juan Ramón Rey Blas; Joan Antoni Gómez-Hospital; Sandra Santos Martínez; Nicolás Manuel Maneiro-Melón; Roberto Mateos Gaitán; Jessika González D'Gregorio; Luisa Salido; José L Mestre; Marcelo Sanmartín; Ángel Sánchez-Recalde
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2020-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.